Tuberculous Meningitis

Medical Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be based on the individual patient's condition, available evidence, and the clinician's judgment. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care.

Overview

• Definition: Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis, resulting from Mycobacterium tuberculosis infection of the leptomeninges and brain parenchyma. It is characterized by inflammation of the meninges and potential involvement of brain structures, leading to a subacute or chronic meningoencephalitis.
• Epidemiology:
  • Global Burden: TBM is a significant public health problem, especially in regions with a high burden of tuberculosis (TB) and HIV. It accounts for approximately 5-10% of all extrapulmonary TB cases.
  • Incidence: Estimated at 1.5 cases per 100,000 population globally, with much higher rates in endemic areas (e.g., sub-Saharan Africa, Southeast Asia) and among specific risk groups.
  • Demographics: Affects all age groups but is disproportionately common in young children (under 5 years) and individuals with compromised immune systems, particularly those with HIV co-infection. HIV-positive individuals have a 20-30 times higher risk of TBM.
• Classification: TBM severity is often classified using the British Medical Research Council (MRC) Staging System, which is crucial for prognosis and treatment guidance:
  • Stage I (Early): Non-specific symptoms, alert and oriented, no focal neurological deficits. May include headache, low-grade fever, malaise.
  • Stage II (Moderate): Mild to moderate altered mental status (e.g., lethargy, confusion), minor focal neurological signs (e.g., cranial nerve palsies, mild paresis). No stupor or coma.
  • Stage III (Advanced): Severe altered mental status (e.g., stupor, coma), severe focal neurological deficits (e.g., hemiplegia, paraplegia, decerebrate rigidity), signs of increased intracranial pressure (ICP) such as papilledema.

Pathophysiology

• Mechanism:
  • TBM typically results from hematogenous dissemination of M. tuberculosis from a primary focus (often pulmonary) to the central nervous system (CNS).
  • The bacilli deposit in the brain parenchyma or subarachnoid space, forming small subpial or subependymal foci known as Rich foci.
  • Rupture of these Rich foci into the subarachnoid space leads to the release of mycobacteria and their antigens, triggering a severe inflammatory response.
  • This inflammation causes exudate formation, particularly at the base of the brain, leading to:
    • Meningitis: Inflammation of the leptomeninges.
    • Arteritis/Vasculitis: Inflammation and occlusion of blood vessels (especially medium-sized arteries like the circle of Willis branches), leading to ischemic infarcts.
    • Hydrocephalus: Obstruction of CSF flow due to inflammatory exudate blocking the basal cisterns or impaired CSF reabsorption at the arachnoid villi.
    • Tuberculomas: Granulomatous masses forming within the brain parenchyma.
    • Cranial nerve involvement: Impingement or damage by basal exudate.
• Risk Factors:
  • HIV infection (most significant risk factor)
  • Malnutrition
  • Immunosuppression (e.g., organ transplant recipients, individuals on TNF-alpha inhibitors, high-dose corticosteroids)
  • Diabetes mellitus
  • Chronic kidney disease (ESRD)
  • Silicosis
  • Extremes of age (young children and elderly)
  • Close contact with individuals with active pulmonary TB
  • Alcoholism, substance abuse
• Protective Factors:
  • Healthy immune system
  • BCG vaccination (confers partial protection, particularly against severe forms like TBM and disseminated TB in children)
  • Early diagnosis and treatment of latent TB infection (LTBI) in high-risk individuals
  • Effective public health programs for TB control (e.g., contact tracing, active case finding, rapid treatment initiation)

Clinical Presentation

Signs and Symptoms

TBM typically has an insidious onset, evolving over 2-8 weeks, contrasting with the acute onset of bacterial meningitis.

• Cardinal Features:
  • Headache (persistent, dull, progressive, often worse in the morning)
  • Low-grade fever (may be absent in immunosuppressed patients)
  • Neck stiffness/meningismus (less pronounced than in bacterial meningitis)
  • Altered mental status (lethargy, confusion, irritability, personality changes)
• Early Signs (Prodromal Stage - Weeks 1-2):
  • Non-specific malaise, fatigue
  • Anorexia, weight loss
  • Irritability, apathy, withdrawal
  • Mild, persistent headache
  • Occasional vomiting
• Advanced Signs (Meningitic Stage - Weeks 3-4 onwards):
  • More severe headache
  • Marked neck stiffness
  • Persistent vomiting
  • Cranial nerve palsies (especially III, IV, VI, VII - ophthalmoplegia, facial palsy)
  • Focal neurological deficits (hemiparesis, monoparesis)
  • Seizures
  • Signs of increased ICP (papilledema, Cushing's triad: bradycardia, hypertension, irregular respiration - late sign)
  • Progressive deterioration of consciousness (stupor, coma)
  • Decorticate or decerebrate posturing
• Atypical Presentations:
  • Acute onset (especially in children or highly immunocompromised individuals)
  • Pure spinal cord involvement (tuberculous myelitis)
  • Stroke-like presentation due to vasculitis and infarcts
  • Presentation with isolated tuberculoma without clear meningitic signs
  • Choroidal tubercles (retinal examination finding)
  • Normal CSF in very early stages or "spinal block" due to thick exudate

Physical Examination

• Inspection:
  • General appearance: May appear chronically ill, malnourished, cachectic.
  • Level of consciousness: Ranges from alert to comatose, assess using GCS.
  • Signs of TB elsewhere (e.g., lymphadenopathy, signs of pulmonary TB).
• Palpation:
  • Nuchal rigidity: Resistance to passive neck flexion (meningismus).
  • Fontanelle fullness in infants.
• Special Tests:
  • Kernig's sign: Pain and resistance on extending the knee with the hip flexed to 90 degrees.
  • Brudzinski's sign: Involuntary flexion of the hips and knees when the neck is passively flexed.
  • Fundoscopic examination: Crucial for detecting papilledema (suggests increased ICP) or choroidal tubercles (pathognomonic but rare, seen in 1-2% of cases).
  • Cranial nerve examination: Look for palsies (especially ocular movements, facial weakness).
  • Motor and sensory examination: Assess for focal neurological deficits, spasticity, abnormal reflexes.

Diagnostic Approach

TBM diagnosis is challenging due to its non-specific symptoms, insidious onset, and difficulties in confirming the pathogen. A high index of suspicion is critical.

History Taking

• Key Questions:
  • Duration and progression of symptoms: Emphasize subacute onset of headache, fever, and neurological changes.
  • Prior TB exposure: Contact with active TB cases.
  • History of TB: Previous TB disease, latent TB infection treatment.
  • Risk factors: HIV status, use of immunosuppressants, chronic diseases (diabetes, renal failure), travel to endemic areas, residence in high-incidence communities.
  • Constitutional symptoms: Weight loss, night sweats, anorexia.
  • Meningeal symptoms: Headache, photophobia, phonophobia, neck stiffness.
  • Neurological symptoms: Changes in mental status, seizures, focal weakness, vision changes.
• Red Flags:
  • Rapid deterioration of consciousness or neurological function.
  • Signs of significantly increased ICP (e.g., decreasing GCS, bradycardia, hypertension).
  • New onset seizures.
  • Sudden focal neurological deficits.

Laboratory Tests

• First-Line:
  • Lumbar Puncture (LP): CSF analysis is paramount, but results can vary, especially in early stages or immunosuppressed patients.
    • Opening pressure: Often elevated (>180 mmH2O), particularly with hydrocephalus.
    • Cell count: Typically 100-500 cells/µL, predominantly lymphocytes (70-90%). Early in disease, polymorphonuclear cells may predominate (transitional pleocytosis). Cell count can be lower in immunosuppressed patients.
    • Protein: Elevated, usually >100 mg/dL, often 200-400 mg/dL (can be >1000 mg/dL in severe cases or with spinal block).
    • Glucose: Low (<45 mg/dL or CSF:blood glucose ratio <0.5). Typically much lower than bacterial meningitis (often <20 mg/dL).
    • CSF Adenosine Deaminase (ADA): Elevated levels (>8-10 U/L) are highly suggestive of TBM, especially in endemic areas. Sensitivity 90%, specificity 90% (cutoff varies).
    • CSF Polymerase Chain Reaction (PCR) for M. tuberculosis:
      • Xpert MTB/RIF (GeneXpert): Recommended by WHO. Rapid (2 hours), identifies M. tuberculosis complex DNA and rifampicin resistance. Sensitivity is variable (around 60-80% for single LP, higher with larger CSF volume or multiple samples), specificity >95%.
      • Line Probe Assay (LPA): Can detect TB and resistance to isoniazid and rifampicin rapidly from culture isolates or directly from CSF.
    • Acid-Fast Bacilli (AFB) Smear: Low sensitivity (10-25%) due to low bacillary load in CSF. Requires large volume of CSF (5-10 mL, spun down) and careful examination.
    • Mycobacterial Culture: Gold standard for definitive diagnosis and drug susceptibility testing (DST). Sensitivity 50-70%. Results take 2-6 weeks (solid media) or 1-3 weeks (liquid media).
  • Blood Tests:
    • Complete Blood Count (CBC): May show mild anemia, normal or elevated white cell count.
    • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Often elevated, non-specific markers of inflammation.
    • HIV testing: Essential in all TBM suspects.
    • Tuberculin Skin Test (TST) or Interferon-Gamma Release Assay (IGRA): Can be negative in active TBM, especially in advanced disease or immunocompromised patients. Positive results support TB diagnosis but do not confirm TBM.
• Confirmatory:
  • Positive CSF mycobacterial culture (definitive).
  • Positive CSF Xpert MTB/RIF (highly suggestive, especially with rifampicin resistance).
  • Histopathological evidence of granulomatous inflammation with caseation necrosis from brain biopsy (if tuberculoma is present and accessible).
• Monitoring:
  • Repeat LP: May be performed to assess response to treatment (e.g., decreasing cell count, rising glucose).
  • Liver function tests (LFTs) and renal function tests (RFTs): For monitoring drug toxicity.
  • Electrolytes: For detecting Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), a common complication.
  • Visual acuity and color vision tests: For ethambutol toxicity.
  • Audiometry: If aminoglycosides are used.

Imaging

• Recommended:
  • Contrast-enhanced Magnetic Resonance Imaging (MRI) of the brain: Preferred imaging modality.
    • Key findings:
      • Basal meningeal enhancement: Classic finding, particularly in the basal cisterns, often with extension into the Sylvian fissures.
      • Hydrocephalus: Communicating or non-communicating, due to basal exudate or aqueductal stenosis.
      • Infarcts: Ischemic lesions, typically in the basal ganglia, thalamus, or internal capsule, due to vasculitis affecting perforating arteries.
      • Tuberculomas: Single or multiple ring-enhancing lesions, often with surrounding edema.
      • Optochiasmatic arachnoiditis: Inflammation around the optic chiasm.
      • Diffusion-weighted imaging (DWI) can show restricted diffusion in infarcts or abscesses.
  • Contrast-enhanced Computed Tomography (CT) of the brain: Can be used if MRI is unavailable or contraindicated.
    • Key findings: Similar to MRI but less sensitive for subtle meningeal enhancement or small lesions. Shows hydrocephalus, infarcts, and tuberculomas.
  • Chest X-ray (CXR): To identify active or past pulmonary TB, as a potential source of dissemination. Findings are present in about 50-70% of TBM cases.
• Advanced:
  • Spinal MRI: If spinal cord involvement (tuberculous myelitis or arachnoiditis) is suspected based on neurological examination.
  • MR Angiography/Venography: To evaluate for severe vasculitis or venous sinus thrombosis if stroke is suspected.

Management

Management of TBM is complex, requiring prompt initiation of antitubercular therapy (ATT) and adjunctive corticosteroids, along with supportive care and management of complications.

Acute Management

• Immediate (within hours of suspicion):
  • Initiate empiric anti-tuberculous therapy (ATT) without waiting for microbiological confirmation, especially in high-risk patients or those with CSF findings suggestive of TBM.
  • Start adjunctive corticosteroids (dexamethasone) in all patients, irrespective of HIV status or MRC stage, unless contraindicated.
• Stabilization (early management priorities):
  • Maintain airway, breathing, and circulation (ABCs).
  • Assess and manage increased ICP: Elevate head of bed, monitor neurological status. Consider mannitol or hypertonic saline if signs of herniation.
  • Manage seizures: Administer anticonvulsants if seizures occur (e.g., IV lorazepam, then phenytoin or levetiracetam).
  • Address hyponatremia: Often due to SIADH; restrict fluids, administer hypertonic saline cautiously if severe.
  • Nutritional support.
• Emergency:
  • Neurosurgical consultation: For patients with severe hydrocephalus leading to clinical deterioration or brain herniation. Ventriculoperitoneal shunt placement may be necessary.
  • Drainage of large tuberculomas causing mass effect if medically refractory.

Chronic Management

• Pharmacological:
  • Anti-Tuberculous Therapy (ATT):
    • Standard Regimen: WHO recommends a 12-month regimen for drug-susceptible TBM.
      • Intensive Phase (2 months): Four drugs – Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), Ethambutol (EMB).
      • Continuation Phase (10 months): Two drugs – Isoniazid (INH) and Rifampicin (RIF).
    • Specific Dosages (Adults, typical):
      • Rifampicin (RIF): 10 mg/kg/day (max 600 mg/day)
      • Isoniazid (INH): 5 mg/kg/day (max 300 mg/day)
      • Pyrazinamide (PZA): 25 mg/kg/day (max 2000 mg/day)
      • Ethambutol (EMB): 15 mg/kg/day (max 1200 mg/day)
      • Note: For CNS penetration, higher doses might be considered by some experts, but standard doses are generally effective.
    • Duration: A 9-12 month regimen is generally recommended. For severe cases (MRC stage III, or those with tuberculomas, or immunocompromised), 12 months is preferred, sometimes even longer (18-24 months) if response is slow.
  • Adjunctive Corticosteroids (Dexamethasone):
    • Indication: Recommended for all patients with TBM, regardless of MRC stage or HIV status, as it reduces mortality and residual neurological deficits.
    • Dosage:
      • Adults: Initially 0.4 mg/kg/day IV for 1-2 weeks, followed by a gradual taper over 6-8 weeks (or longer, up to 3 months). A typical tapering schedule might be:
        • Week 1-2: 0.4 mg/kg/day IV
        • Week 3-4: 0.3 mg/kg/day IV
        • Week 5-6: 0.2 mg/kg/day IV
        • Week 7-8: 0.1 mg/kg/day IV
        • Then switch to oral equivalent and taper over another 4-6 weeks (e.g., 4 mg/day orally for 2 weeks, then 2 mg/day for 2 weeks, then 1 mg/day for 2 weeks).
      • Children: Similar weight-based dosing.
    • Mechanism: Reduces inflammation, exudate formation, cerebral edema, and vasculitis.
  • Adjunctive Pyridoxine (Vitamin B6): 25-50 mg/day, always given with INH to prevent peripheral neuropathy.
  • Management of Drug-Resistant TBM: Guided by DST results. Involves second-line anti-TB drugs (e.g., fluoroquinolones, injectable agents like amikacin or capreomycin, bedaquiline, pretomanid, linezolid) with prolonged treatment durations (18-24 months or more).
• Non-pharmacological:
  • Nutritional support: Address malnutrition.
  • Rehabilitation: Physical, occupational, and speech therapy for patients with residual neurological deficits.
  • Psychological support.
• Monitoring:
  • Clinical: Regular assessment of neurological status, GCS, signs of increased ICP, and drug side effects.
  • Laboratory:
    • Monthly LFTs for hepatotoxicity (esp. with INH, RIF, PZA).
    • Renal function.
    • Electrolytes (esp. Na for SIADH).
    • Visual acuity and color vision (for EMB).
    • Audiometry (if ototoxic drugs used).
  • Imaging: Repeat brain imaging (MRI or CT) typically after 2-3 months of treatment or if clinical deterioration occurs, to assess hydrocephalus, tuberculoma resolution, and infarcts.
  • CSF: Repeat LP may be considered if clinical response is poor or to assess for paradoxical worsening (IRIS).

Treatment Algorithms

• First-Line:
  1. Suspicion of TBM (based on clinical picture, CSF findings, imaging).
  2. Immediate initiation of 4-drug ATT + Dexamethasone.
     • Adults: RIF, INH, PZA, EMB + Dexamethasone (0.4 mg/kg/day IV, tapering).
     • Children: Weight-based dosing for ATT, and Dexamethasone (0.4 mg/kg/day IV, tapering).
  3. Lumbar puncture and CSF analysis: Send for Xpert MTB/RIF, AFB smear, culture, ADA, cell count, protein, glucose.
  4. Baseline investigations: HIV, LFTs, RFTs, electrolytes, CXR, brain imaging.
  5. Adjust treatment based on DST results:
     • If drug-susceptible: Continue standard 12-month regimen.
     • If drug-resistant: Shift to individualized second-line regimen.
  6. Manage complications: Hydrocephalus, seizures, hyponatremia.
• Second-Line (for drug-resistant TBM or intolerance):
  • Guided by DST results. Typically involves at least 4 effective drugs to which the isolate is susceptible.
  • May include fluoroquinolones (levofloxacin, moxifloxacin), injectable agents (amikacin, capreomycin, kanamycin), bedaquiline, linezolid, clofazimine, cycloserine, delamanid, etc.
  • Duration is prolonged (18-24 months or more).
• Refractory Cases:
  • Persistent hydrocephalus: Requires ventriculoperitoneal shunt.
  • Paradoxical worsening (IRIS): Exacerbation of symptoms or new lesions due to immune reconstitution (especially in HIV-co-infected patients starting ART). Managed with increased corticosteroid dose (e.g., restarting or increasing dexamethasone). Continue ATT. Do not stop anti-retroviral therapy (ART).
  • Persistent tuberculomas: Usually resolve with ATT. Rarely, surgical excision may be considered if causing significant mass effect and not responding to medical therapy.
  • Drug resistance: Requires meticulous adjustment of regimen based on comprehensive DST.

Complications

TBM is associated with high morbidity and mortality due to significant neurological damage.

• Common:
  • Hydrocephalus: Occurs in 60-80% of patients due to basal exudate blocking CSF flow or impaired absorption. Can be communicating or non-communicating.
  • Cranial nerve palsies: Most commonly optic (II), oculomotor (III), trochlear (IV), abducens (VI), and facial (VII) nerves due to entrapment in basal exudate. Can lead to visual impairment or blindness.
  • Stroke: Ischemic infarcts in 20-50% of cases due to inflammatory vasculitis (tuberculous arteritis) affecting arteries, especially those supplying the basal ganglia, thalamus, and internal capsule.
  • Seizures: Due to cortical irritation from inflammation, infarcts, or tuberculomas.
  • Tuberculomas: Intracranial granulomas, can cause focal neurological deficits and seizures.
  • Hyponatremia: Often due to SIADH (syndrome of inappropriate antidiuretic hormone secretion).
• Serious:
  • Brain herniation: Due to severe hydrocephalus or mass effect from tuberculomas/edema, leading to brainstem compression and death.
  • Severe neurological deficits: Hemiplegia, quadriparesis, severe cognitive impairment, blindness, deafness.
  • Drug-induced hepatotoxicity: From ATT.
  • Immune Reconstitution Inflammatory Syndrome (IRIS): A paradoxical worsening of clinical signs or appearance of new lesions due to a recovering immune system, particularly in HIV-co-infected patients on ART.
• Long-term:
  • Cognitive impairment (memory, executive function)
  • Epilepsy
  • Visual or hearing impairment/blindness/deafness
  • Endocrinopathies (e.g., adrenal insufficiency due to prolonged steroid use or direct pituitary involvement)
  • Psychiatric sequelae (depression, anxiety, personality changes)
  • Spasticity and movement disorders

Prognosis

TBM remains a devastating disease with high mortality and significant long-term morbidity.

• Factors Affecting Outcome:
  • Stage at presentation: Most crucial prognostic factor.
    • Stage I: Mortality <5%, good neurological outcome in >90%.
    • Stage II: Mortality 15-20%, neurological deficits in 20-30%.
    • Stage III: Mortality 50-70%, severe neurological deficits in >50% of survivors.
  • Age: Worse prognosis in very young children and the elderly.
  • HIV co-infection: Higher mortality (up to 70-80% in advanced stages) and worse neurological outcomes, increased risk of paradoxical IRIS.
  • Delay in diagnosis and treatment: Prognosis worsens significantly with delayed ATT.
  • Drug resistance: Significantly complicates treatment and worsens outcome.
  • Presence of complications: Hydrocephalus, stroke, severe vasculitis.
  • CSF characteristics: Very low glucose, very high protein, or very high cell count are associated with poorer outcomes.
• Survival: Overall mortality rate remains high, ranging from 15-70% depending on geographical region and patient population.
• Quality of Life: A high proportion of survivors (30-50%) experience significant neurological sequelae, impacting their quality of life, functional independence, and cognitive abilities.

Prevention

• Primary Prevention: Aimed at preventing initial M. tuberculosis infection or progression to active disease.
  • BCG Vaccination: While its efficacy against pulmonary TB is variable, BCG consistently reduces the risk of severe forms of TB in children, including TBM and disseminated TB. Recommended for infants in high-burden countries.
  • TB Infection Control: In healthcare settings and communities (e.g., prompt diagnosis and treatment of active pulmonary TB, respiratory hygiene, adequate ventilation).
  • Improved socio-economic conditions: Reducing poverty, malnutrition, and overcrowding.
• Secondary Prevention: Early detection and intervention to prevent progression to severe disease.
  • Latent TB Infection (LTBI) Treatment: Identifying and treating LTBI in high-risk individuals (e.g., household contacts of active TB cases, immunosuppressed patients, HIV-infected individuals) can prevent progression to active TB, including TBM. Regimens include 6-9 months of INH or 3-4 months of RIF.
  • Active Case Finding: Prompt diagnosis and effective treatment of active TB cases to reduce transmission.
• Tertiary Prevention: Preventing complications and reducing morbidity/mortality once TBM has occurred.
  • Prompt diagnosis and initiation of appropriate ATT + corticosteroids.
  • Aggressive management of complications like hydrocephalus and seizures.
  • Rehabilitation to maximize functional recovery.

Special Populations

• Pediatric:
  • Diagnosis: More challenging due to non-specific symptoms, difficulty in obtaining history, and higher incidence of atypical presentations (e.g., seizures, focal neurological signs before meningitic signs). CSF findings may also be less typical.
  • Dosing: All drug dosages must be strictly weight-based. Children may metabolize RIF and INH faster, sometimes requiring higher mg/kg doses.
  • Complications: Higher risk of hydrocephalus, neurological sequelae, and developmental delays.
  • Prognosis: Worse prognosis in very young children.
• Geriatric:
  • Diagnosis: Often presents atypically with confusion, subtle neurological signs, or general decline without classic meningeal symptoms. Comorbidities and polypharmacy can complicate diagnosis and management.
  • Complications: Higher risk of drug toxicities, including hepatotoxicity. Increased risk of falls and delirium.
  • Drug interactions: Careful consideration of interactions between ATT drugs and medications for comorbidities.
• Pregnancy:
  • Diagnosis: Similar to non-pregnant adults.
  • Management: TBM in pregnancy is serious for both mother and fetus.
    • ATT: RIF, INH, PZA, EMB are generally considered safe during pregnancy. Streptomycin is contraindicated due to risk of ototoxicity in the fetus. Pyridoxine supplementation (25-50 mg/day) is essential with INH.
    • Corticosteroids: Dexamethasone is generally considered safe.
    • Delivery: Vaginal delivery preferred if stable; C-section if neurological deterioration or obstetrical indications.
    • Breastfeeding: INH, RIF, PZA, EMB are generally considered safe while breastfeeding, but the infant should be monitored.
• Comorbidities:
  • HIV Co-infection:
    • Increased incidence, higher bacillary load in CSF, often atypical CSF findings (e.g., lower CSF glucose, normal or higher cell count depending on CD4 count).
    • Higher mortality.
    • Immune Reconstitution Inflammatory Syndrome (IRIS): Common complication (20-40% of HIV-TBM patients) after starting ART. ART should be started 2-8 weeks after initiating ATT, depending on severity and CD4 count. For patients with CD4 <50 cells/mm3, WHO recommends starting ART within 2 weeks after ATT initiation. Close monitoring for IRIS, often requiring increased steroids.
    • Drug interactions between ART and RIF (RIF induces metabolism of many ART drugs). Consider dose adjustments or alternative ART regimens (e.g., using efavirenz or dolutegravir-based regimens) or alternative TB drugs if severe interactions.
  • Diabetes Mellitus: Increased risk of TBM, potential for more severe disease and delayed recovery. Careful monitoring of blood glucose during corticosteroid therapy.
  • Renal/Hepatic Impairment: Requires drug dosage adjustments for renally or hepatically excreted drugs (e.g., INH, PZA, EMB in renal failure; INH, RIF, PZA in hepatic failure). PZA is generally contraindicated in severe liver disease.

Clinical Pearls

• Diagnostic:
  • Think TBM in subacute meningitis: Headache and fever for more than 2 weeks, especially if accompanied by subtle neurological changes or a history of TB exposure/risk factors. Do not rule out TBM simply because AFB smear is negative.
  • Classic CSF profile: Lymphocytic pleocytosis, low glucose, high protein, but remember variations, especially in early disease or immunosuppression.
  • CSF ADA: A valuable adjunctive diagnostic tool, especially in high-prevalence settings. A value >8-10 U/L is highly suggestive.
  • Xpert MTB/RIF: Has revolutionized rapid diagnosis but its sensitivity is not 100%; a negative result does not rule out TBM.
  • Imaging clues: Basal meningeal enhancement, hydrocephalus, and infarcts (especially in the basal ganglia) on MRI are highly suggestive.
• Treatment:
  • Prompt empiric treatment: Start ATT and corticosteroids immediately upon clinical suspicion. Delay increases mortality and morbidity.
  • Corticosteroids are vital: Dexamethasone reduces mortality and disability. Do not omit, unless clear contraindications.
  • Full 12-month regimen: Adherence is crucial for preventing relapse and drug resistance.
  • Monitor for IRIS: In HIV-co-infected patients starting ART, prepare to manage paradoxical worsening with increased steroids.
  • Pyridoxine: Always co-administer with INH to prevent neuropathy.
• Pitfalls:
  • Delay in diagnosis: Often confused with viral meningitis or other neurological conditions due to insidious onset and non-specific symptoms.
  • Over-reliance on negative AFB smear or culture: These tests have low sensitivity. A negative result does not exclude TBM.
  • Inadequate CSF sampling: Using too little CSF or not centrifuging adequately can lead to false negatives. At least 5-10 mL is recommended for microscopy and culture.
  • Discontinuation of steroids too early: Can lead to rebound inflammation.
  • Under-recognition of drug resistance: Failure to improve despite appropriate treatment should prompt suspicion of drug resistance and re-evaluation with DST.

Recent Updates

• Guidelines:
  • WHO Consolidated Guidelines on Tuberculosis (2020, 2022 updates): Emphasize the crucial role of corticosteroids (dexamethasone) for all TBM patients, regardless of HIV status or disease severity. Reinforce the use of Xpert MTB/RIF as a first-line diagnostic test for TBM.
  • Updates on Drug-Resistant TB regimens: Shorter all-oral regimens for DR-TB (e.g., BPaL/M regimens) are being increasingly adopted, which may impact future TBM regimens for drug-resistant cases.
• Evidence:
  • Randomized controlled trials (RCTs) continue to support the benefit of adjunctive corticosteroids in reducing mortality and neurological disability in TBM.
  • Role of higher-dose rifampicin: Emerging evidence suggests potential benefits of higher-dose rifampicin (e.g., 15-35 mg/kg) in TBM to improve CNS penetration, but this is not yet standard clinical practice and requires further research.
  • Novel diagnostics: Research into host biomarkers (e.g., CSF IFN-gamma, IP-10) and next-generation sequencing for rapid diagnosis is ongoing.
• Controversies:
  • Optimal timing of ART in HIV-TBM: While current guidelines favor early ART (within 2 weeks) for low CD4 counts, some debate remains regarding the ideal balance between reducing IRIS risk and improving overall outcomes.
  • Duration of corticosteroid therapy: While 6-8 weeks is standard, some experts advocate for longer courses in specific severe cases or those with ongoing inflammation on imaging.
  • Role of neurosurgery for tuberculomas: Whether to surgically remove symptomatic tuberculomas or rely solely on medical management is often a case-by-case decision.

Key References

• Guidelines:
  • World Health Organization (WHO). WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment – Drug-Susceptible Tuberculosis Treatment. Geneva: World Health Organization; 2022.
  • World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 2: Screening – Latent TB Infection. Supplement: Management of tuberculosis meningitis. Geneva: World Health Organization; 2020.
  • Centers for Disease Control and Prevention (CDC). Treatment for TB Disease Fact Sheet. (Refer to their updated guidelines for specific regimens).
• Studies:
  • Thwaites GE, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004 Oct 21;351(17):1741-51. (Landmark MRC-funded trial)
  • Donovan J, et al. Early-start antiretroviral therapy and the incidence of immune reconstitution inflammatory syndrome in HIV-associated tuberculous meningitis. Clin Infect Dis. 2017 Jul 1;65(1):154-158.
  • Chang CM, et al. Diagnostic accuracy of GeneXpert MTB/RIF for tuberculous meningitis: A systematic review and meta-analysis. J Infect. 2017 Jun;74(6):534-541.
• Reviews:
  • Marx GE, et al. Tuberculous meningitis: Diagnosis and treatment. Lancet Neurol. 2017 Sep;16(9):764-775.
  • Thwaites GE, et al. Tuberculous meningitis: Current issues in diagnosis and management. J Infect. 2009 Dec;59(6):387-94.
  • Marais S, et al. Tuberculous meningitis. Handb Clin Neurol. 2018;152:117-134.